• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

OPINIONI - Opinions

Volume:

Biochimica Clinica 2021; 45(4) 400-407

Pubblicato on-line:

Settembre 14, 2021

DOI:

10.19186/BC_2021.061

Scarica in PDF:

Elementi utili per implementare un sistema per il controllo dell’accuratezza dei risultati nella diagnostica di SARS-COV-2 (RNA virale, antigeni e anticorpi)
Useful elements for implementing a system to control the accuracy of results in the diagnosis of SARS-CoV-2 (viral RNA, antigens and antibodies)

AUTORI

Sonia Maria Mattioli1, Massimo Quercioli2, Sabrina Buoro3, Patrizia Pecile4, Maria Grazia Colao5, Elena Pariani6, Cosimo Ottomano7, Duilio Brugnoni8
1Laboratorio di Patologia Clinica ASST Valcamonica, Esine (BS)
2Synlab, Italia
Centro di Riferimento Regionale per la Qualità dei Servizi di Medicina di Laboratorio, ASST Grande Ospedale Metropolitano Niguarda, Milano
4Synlab Med, Calenzano (FI)
5Laboratorio di Microbiologia e Virologia, Azienda Ospedaliero Universitaria Careggi (AOUC), Firenze
6Dipartimento di Scienze Biomediche per la Salute, Università degli studi di Milano
7IRCSS Fondazione per l'Alta Ricerca e l'Alta Formazione in Diagnostica Nucleare (SDN), Napoli
8Laboratorio Centrale di Analisi Chimico cliniche ASST Spedali Civili, Brescia

ABSTRACT

Useful elements for implementing a system to control the accuracy of results in the diagnosis of SARS-CoV-2 (viral RNA, antigens and antibodies)

As SARS-CoV-2 swiftly spread globally becoming a pandemic, the urgent need to provide a laboratory diagnosis of the infection – to allow both the clinical management of individual patients and to monitor the outbreak in the community by health authorities – arose. This resulted in a rapid development of diagnostic tests – promptly available on the market – including methods for the direct detection of the virus in biological samples (molecular and antigenic tests) and for indirect detection by documenting a contact with SARS-CoV-2 (serological antibodies tests). To fast-track the availability of these tests, an “emergency” authorization was issued for their use in medical laboratories, which then resulted in the urge to verify their reliability and to monitor carefully their performances, in order to avoid the risk to provide inaccurate results. This document illustrates the main potential sources of error, which can be pre-pre-analytical (i.e. test utilization in an incorrect diagnostic window), pre-analytical (i.e. incorrect collection, manipulation, sample transport and storage), analytical (i.e. pipetting errors during manual sample dispensing, incorrect RNA extraction, cDNA synthesis and amplification) and post-analytical (i.e. incorrect test report and interpretation). Furthermore, the key elements for creating a system to keep continuously under control these potential sources of error are presented, both implementing an adequate control of the entire process and a system for monitoring the analytical quality, where Internal Quality Control plays a crucial role.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967